1. Signaling Pathways
  2. Neuronal Signaling
  3. Monoamine Oxidase

Monoamine Oxidase

Oxidase

MAO

Monoamine oxidases (MAO) are a family of enzymes that catalyze the oxidation of monoamines. They are found bound to the outer membrane of mitochondria in most cell types in the body. They belong to the protein family of flavin-containing amine oxidoreductases. Monoamine oxidases catalyze the oxidative deamination of monoamines. Oxygen is used to remove an amine group from a molecule, resulting in the corresponding aldehyde and ammonia. Monoamine oxidases contain the covalently bound cofactor FAD and are, thus, classified as flavoproteins. Because of the vital role that MAOs play in the inactivation of neurotransmitters, MAO dysfunction is thought to be responsible for a number of psychiatric and neurological disorders. MAO-A inhibitors act as antidepressant and antianxiety agents, whereas MAO-B inhibitors are used alone or in combination to treat Alzheimer’sand Parkinson’s diseases.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-151388
    hMAO-B/MB-COMT-IN-1
    Inhibitor 98.04%
    hMAO-B/MB-COMT-IN-1 is a dual MAO-B/MB-COMT inhibitor (IC50s: 2.5 μΜ for hMAO-B, 3.84 μΜ for MB-COMT). hMAO-B/MB-COMT-IN-1 protects cells against oxidative damage. hMAO-B/MB-COMT-IN-1 can be used in the research of neurodegeneration disease, such as Parkinson’s Disease (PD).
    hMAO-B/MB-COMT-IN-1
  • HY-B1413
    Eprobemide
    Inhibitor 99.94%
    Eprobemide is a non-competitive reversible inhibitor of monoamine oxidase A.
    Eprobemide
  • HY-N7598
    Chrysophanol-1-O-β-gentiobioside
    Inhibitor ≥99.0%
    Chrysophanol-1-O-β-gentiobioside, an anthraquinone glycoside isolated from Cassia obtusifolia seeds. Chrysophanol-1-O-β-gentiobioside shows selective inhibition of hMAO-A isozyme activity (IC50=96.15 μM).
    Chrysophanol-1-O-β-gentiobioside
  • HY-156255
    MAO-B-IN-25
    Inhibitor 99.11%
    MAO-B-IN-25 (compound 92) is a selective MAO-B inhibitor with IC50s of 0.5 nM and 240 nM for MAO-A and MAO-B, respectively.
    MAO-B-IN-25
  • HY-B1558A
    Bifemelane hydrochloride
    Inhibitor 99.86%
    Bifemelane hydrochloride (MCI-2016) is a potent, selective and competitive inhibitor of monoamine oxidase A (MAO-A), with a Ki of 4.20 μM. Bifemelane hydrochloride also inhibits MAO-B noncompetitively with a Ki of 46.0 μM. Bifemelane hydrochloride has a potent antidepressant activity and can be used for the research of cognitive and emotional disturbances related to cerebrovascular disease.
    Bifemelane hydrochloride
  • HY-10400
    Ladostigil hemitartrate
    Inhibitor 98.90%
    Ladostigil (TV-3326) hemitartrate is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with IC50s of 37.1 and 31.8 μM for MAO-B and AChE, respectively. Ladostigil hemitartrate exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil hemitartrate can be used for the research of depression and Alzheimer's disease. Ladostigil (hemitartrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Ladostigil hemitartrate
  • HY-149234
    MAO-B-IN-18
    Inhibitor 99.84%
    MAO-B-IN-18 is a potent and selective MAO B inhibitor with IC50s of 52 nM and 14 μM for hMAO B and hMAO A, respectively. MAO-B-IN-18 enables promising cytoprotective effects against hydrogen peroxide insults in neuroblastoma and astrocytes cultures.
    MAO-B-IN-18
  • HY-14260
    RS 8359
    Inhibitor
    RS 8359 is a selective and reversible MAO-A inhibitor, with antidepressant activity.
    RS 8359
  • HY-B1111
    Amitraz
    Inhibitor 99.65%
    Amitraz is a non-systemic acaricide and insecticide with alpha-adrenergic agonist activity that interacts with octopamine receptors in the central nervous system and inhibits monoamine oxidase and prostaglandin synthesis.
    Amitraz
  • HY-114286
    PXS-5153A
    Inhibitor
    PXS-5153A is a potent, selective, orally active and fast-acting lysyl oxidase like 2/3 enzymatic (LOXL2/LOXL3) inhibitor, with an IC50 of <40 nM for LOXL2 across all mammalian species and an IC50 of 63 nM for human LOXL3. PXS-5153A could reduce crosslinks and ameliorates fibrosis.
    PXS-5153A
  • HY-10399A
    Ladostigil hydrochloride
    Inhibitor 99.94%
    Ladostigil (TV-3326) hydrochloride is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with IC50s of 37.1 and 31.8 μM for MAO-B and AChE, respectively. Ladostigil hydrochloride exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil can be used for the research of depression and Alzheimer's disease. Ladostigil (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Ladostigil hydrochloride
  • HY-14200
    (S)-Rasagiline
    Inhibitor 99.80%
    (S)-Rasagiline (TVP1022) is the relatively inactive S-enantiomer form of Rasagiline. Rasagiline is a highly potent selective irreversible MAO inhibitor with IC50s of 4.43 nM and 412 nM for rat brain MAO B and A activity, respectively. (S)-Rasagiline is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    (S)-Rasagiline
  • HY-100975
    TB5
    Inhibitor 99.96%
    TB5 is a potent, selective and reversible inhibitor of hMAO-B with a Ki value of 0.11±0.01 μM.
    TB5
  • HY-151466
    HIF-1α-IN-5
    Inhibitor 99.95%
    HIF-1α-IN-5 is a HIF-1α inhibitor with an IC50 value of 24 nM (in HEK293T cell). HIF-1α-IN-5 also inhibits MAO-A activity. HIF-1α-IN-5 downregulates VEGF and PDK1 mRNA expressions under hypoxia. HIF-1α-IN-5 can be used in the research of cancer.
    HIF-1α-IN-5
  • HY-122812
    Maesopsin
    Inhibitor 99.66%
    Maesopsin is a phenolic compound, that can be isolated from Hoveniae Lignum.
    Maesopsin
  • HY-B1440
    Ethaverine hydrochloride
    Inhibitor 99.72%
    Ethaverine hydrochloride, a derivative of papaverine, inhibits cardiac L-type calcium channel. Ethaverine hydrochloride is a peripheral vasodilator and antispasmodic agent. Ethaverine hydrochloride can be used for research of peripheral vascular disease.
    Ethaverine hydrochloride
  • HY-N0453R
    Hypericin (Standard)
    Inhibitor
    Hypericin (Standard) is the analytical standard of Hypericin. This product is intended for research and analytical applications. Hypericin is a naturally occurring substance found in Hyperlcurn perforatum L. Hypericin is an inhibitor of PKC (protein kinase C), MAO (monoaminoxidase), dopamine-beta-hydroxylase, reverse transcriptase, telomerase and CYP (cytochrome P450). Hypericin shows antitumor, antiviral, antidepressive activities, and can induce apoptosis.
    Hypericin (Standard)
  • HY-151498A
    PXS-4787 hydrochloride
    Inhibitor 99.71%
    PXS-4787 hydrochloride is a specific and effective pan-LOX (lysyl oxidase) inhibitor for abolishing lysyl oxidase activity. PXS-4787 hydrochloride inhibits LOX with IC50s of 2 μM (Bovine LOX), 3.2 μM (rh LOXL1), 0.6 μM (rh LOXL2), 1.4 μM (rh LOXL3), 0.2 μM (rh LOXL4), respectively. PXS-4787 hydrochloride reduces deposition and crosslinking of collagen I secreted by human fibroblasts.
    PXS-4787 hydrochloride
  • HY-144635
    Nrf2-ARE/hMAO-B/QR2 modulator 1
    Inhibitor 98.44%
    Nrf2-ARE/hMAO-B/QR2 modulator 1 is a Resveratrol-based multitarget-directed ligands with IC50s of 8.05, 9.83 and 0.57 μM for hMAO-B, NRF2 and QR2. Nrf2-ARE/hMAO-B/QR2 modulator 1 has neuroprotection, decreasing ROS production in okadaic acid-treated mice hippocampal slices.
    Nrf2-ARE/hMAO-B/QR2 modulator 1
  • HY-13339
    Brofaromine
    Inhibitor 99.60%
    Brofaromine (CGP 11305A) is a monoamine oxidase (MAO) inhibitor with IC50 of 0.2 μM for MAO-A.
    Brofaromine
Cat. No. Product Name / Synonyms Application Reactivity

MAO-A

MAO-B

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.

Monoamine Oxidase Inhibitors
Product NameMAO-AMAO-BPurity    
Tranylcypromine hydrochloride
MAO-A, IC50: 2.3 μM
MAO-B, IC50: 0.95 μM
99.90%
Selegiline hydrochloride 
MAO-B, IC50: 51 nM
99.94%
Pargyline
MAO-A, Ki: 13 μM
MAO-B, Ki: 0.5 μM
99.92%
Pargyline hydrochloride
MAO-A, Ki: 13 μM
MAO-B, Ki: 0.5 μM
99.91%
Norharmane
MAO-A, IC50: 6.5 μM
MAO-B, IC50: 4.7 μM
99.46%
Rasagiline
rMAO-A, IC50: 412 nM
rMAO-B, IC50: 4.43 nM
99.88%
Safinamide
MAO-A, IC50: 580 μM
MAO-B, IC50: 98 nM
99.89%
Moclobemide
MAO-A, IC50: 6.061
 99.12%
Rasagiline mesylate
rMAO-A, IC50: 412 nM
rMAO-B, IC50: 4.43 nM
99.82%
Tedizolid phosphate
MAO-A
MAO-B
99.65%
Harmane
hMAO-A, IC50: 0.5 μM
MAO-B, IC50: 5 μM
99.91%
1,4-Naphthoquinone
MAO-A, Ki: 7.7 μM
MAO-B, Ki: 1.4 μM
99.97%
Xanthone
MAO-A, IC50: 0.84 μM
 99.97%
Safinamide mesylate
MAO-A, IC50: 580 nM
MAO-B, IC50: 98 nM
99.87%
Desmethoxyyangonin
MAO-A, IC50: 1.850 μM
MAO-B, IC50: 0.123 μM
99.47%
Osthenol
hMAO-A, Ki: 0.26 μM
hMAO-A, IC50: 0.74 μM
 99.27%
(E)-8-(3-Chlorostyryl)caffeine 
MAO-B, Ki: 70 nM
99.4%
Tisolagiline 
MAO-B, IC50: 8 nM
99.97%
Methyl citrate 
MAO-B, IC50: 0.23 mM
≥98.0%
LSD1/HDAC6-IN-2
MAO-A, IC50: 5 nM
MAO-B, IC50: 6600 nM
99.66%
MAO-A inhibitor 1
MAO-A, IC50: 100 μM
 98.55%
MAO-IN-M30 dihydrochloride
MAO-A, IC50: 37 nM
MAO-B, IC50: 57 nM
99.25%
TC-2153
MAO-A
 98.73%
Chrysophanol-1-O-β-gentiobioside
MAO-A, IC50: 96.15 μM
 ≥99.0%
MAO-B-IN-25
MAO-A, IC50: 240 nM
MAO-B, IC50: 0.5 nM
99.11%
Bifemelane hydrochloride
MAO-A, Ki: 4.2 μM
MAO-B, Ki: 46 μM
99.86%
Ladostigil hemitartrate 
MAO-B, IC50: 37.1 nM
98.90%
MAO-B-IN-18
hMAO-A, IC50: 14 μM
hMAO-B, IC50: 52 nM
99.84%
Ladostigil hydrochloride 
MAO-B, IC50: 37.1 μM
99.94%
MAO-A/5-HT2AR-IN-1
MAO-A, IC50: 0.004 ± 0. μM
MAO-B, IC50: 1.05 ± 0.0 μM
99.71%
Ladostigil 
MAO-B, IC50: 37.1 μM
MAO-B-IN-8 
MAO-B
98.03%
Tetrahydroharmine 
MAO-B, IC50: 74 nM
98.00%
ASS234
MAO-A, IC50: 5.2 nM
MAO-B, IC50: 43 nM
99.6%
(Rac)-Rasagiline 
MAO-B
Tetrindole mesylate
MAO-A
 99.93%
MC4762 
MAO-B, IC50: 0.182 μM
Selegiline 
MAO-B, IC50: 51 nM
MAO A/HDAC-IN-1
MAO-A
 
hMAO-B-IN-7 
hMAO-B, IC50: 0.79 μM
MAO-B-IN-39
MAO-A, IC50: >30 μM
MAO-B, IC50: 3.61 μM
MAO-B-IN-21 
MAO-B
MAO-B-IN-37
MAO-A, IC50: 16 μM
MAO-B, IC50: 0.27 μM
Befloxatone
MAO-A, IC50: 4 nM
MAO-B, IC50: 300 nM
Dual AChE-MAO B-IN-2 
MAO-B, Ki: 4.5 μM
AChE-IN-60
MAO-A, IC50: 353 nM
MAO-B, IC50: 716 nM
MAO-A inhibitor 2
MAO-A, IC50: 14.3 μM
MAO-B, IC50: 106 μM
MAO-B-IN-9 
MAO-B, IC50: 0.178 ± 0. μM
99.70%
ChEs/MAOs-IN-2
MAO-A, IC50: 0.10 μM
MAO-B, IC50: 0.20 μM
Esuprone
MAO-A, IC50: 7.3 nM
 
LSD1-IN-17
MAO-A, IC50: 0.028 ± 0. μM
MAO-B, IC50: 0.820 ± 0. μM
(±)-Amiflamine
MAO-A, pIC50: 5.57
 99.23%
MAO-B-IN-13 
MAO-B, IC50: 10 nM
Cimoxatone
MAO-A
 
hMAO-B-IN-11 
hMAO-B, IC50: 0.11 μM
LSD1-IN-34
MAO-A, IC50: 18.46 nM
MAO-B, IC50: 8481.67 nM
PSB-1491 
hMAO-B, IC50: 0.0386 nM
Neuroinflammatory-IN-2 
MAO-B, IC50: 10.30 μM
AChE/BChE/MAO-B-IN-3 
hMAO-B, IC50: 0.0359 μM
MAO-B-IN-33
MAO-A, IC50: 26.805 μM
MAO-B, IC50: 0.021 μM
MAO-IN-6 
MAO-B, IC50: 0.09 μM
AChE/MAO-IN-1
hMAO-A, IC50: 0.1108 μM
hMAO-A, Ki: 0.1069 μM
hMAO-B, IC50: 0.0409 μM
hMAO-B-IN-2 
MAO-B, IC50: 4 nM
MAO-B-IN-16
hMAO-A, IC50: >100 μM
hMAO-B, IC50: 1.55 μM
1-Methyl-2-undecyl-4(1H)-quinolone 
MAO-B, IC50: 15.3 μM
MAO-B, Ki: 9.91 μM
LSD1-IN-15
MAO-A, IC50: 0.028 ± 0. μM
MAO-B, IC50: 0.327 ± 0. μM
CHBO4 
hMAO-B, IC50: 0.031 μM
MAO-B-IN-7 
MAO-B, IC50: 0.3 μM
MAO-B-IN-14 
hMAO-B, IC50: 0.95 μM
hMAO-B, Ki: 0.55 μM
AChE/BChE/MAO-B-IN-2 
MAO-B, IC50: 48.2 nM
MAO-B ligand-1
hMAO-A, IC50: 22.57 nM
hMAO-B, IC50: 3.83 nM
AChE/MAO-B-IN-3 
hMAO-B, IC50: 0.0456 μM
MAO-B-IN-11 
MAO-B, IC50: 1.3 μM
MAO-B-IN-10
MAO-A, IC50: 15.9 ± 0.1 μM
MAO-B, IC50: 5.3 ± 0.22 μM
Multitarget AD inhibitor-2 
MAO-B, IC50: 0.45 μM
Desoxypeganine
MAO-A, IC50: 2 μM
 
HDAC1/MAO-B-IN-1 
MAO-B, IC50: 99.0 nM
MAO-B-IN-3 
MAO-B, IC50: 96 nM
MAO-B-IN-5
MAO-A, IC50: 0.204 μM
MAO-B, IC50: 34.190 μM
LSD1-IN-26
MAO-A, IC50: 1234.57 nM
MAO-B, IC50: 3819.27 nM
Dual AChE-MAO B-IN-3 
MAO-B, IC50: 0.41 ± 0.0 μM
2-PAT
MAO-A, IC50: 0.721 μM
MAO-B, IC50: 14.6 μM
Harmane (Standard)
hMAO-A
MAO-B
MAO-B-IN-40
hMAO-A, IC50: >100 μM
hMAO-B, IC50: 0.493 μM
NDs-IN-1
hMAO-A
hMAO-B
AChE/BChE/MAO-B-IN-5 
MAO-B, IC50: 0.11 μM
MAO-B-IN-20
MAO-A, IC50: >10 μM
MAO-B, IC50: 0.037 μM
MAO-B-IN-38
MAO-A, IC50: 21.46 μM
MAO-B, IC50: 0.03 μM
AChE/BChE-IN-6 
hMAO-B, IC50: > 100 μM
1-Methyl-2-nonyl-4(1H)-quinolone
MAO-A
MAO-B
MAO-B-IN-17
hMAO-A, IC50: >100 μM
hMAO-B, IC50: 5.08 μM
≥99.0%
MAO-B-IN-32 
MAO-B, IC50: 16 nM
AChE/BuChE/MAO-B-IN-1 
hMAO-B, IC50: 1.11 μM
Tisolagiline methylsulfate 
MAO-B, IC50: 8 nM
Moclobemide N-Oxide
MAO-A
 
FTEAA
MAO-A, IC50: 0.52 μM
MAO-B, IC50: 1.02 μM
MAO A/HSP90-IN-2
MAO-A, IC50: 4.58 μM
 
MAO-B-IN-6
MAO-A, IC50: 46.365 μM
MAO-B, IC50: 0.019 μM
MAO-B-IN-30
MAO-A, IC50: 19.176 μM
MAO-B, IC50: 0.082 μM
98.53%
Monoamine Oxidase B inhibitor 5
hMAO-A, IC50: 26014 nM
hMAO-B, IC50: 67.3 nM
Monoamine Oxidase B inhibitor 6 
MAO-B, IC50: 0.11 μM
MAO-B, Ki: 0.072 μM
LSD1-IN-12
MAO-A, Ki: 2.3 μM
MAO-B, Ki: 3.5 μM
AChE/BChE/MAO-B-IN-1 
MAO-B, IC50: 26.1 μM
99.57%
MAO-A/B-IN-3
MAO-A, IC50: 67 nM
MAO-B, IC50: 29 nM
MAO-B-IN-19 
MAO-B, IC50: 0.67 μM
MAO-B-IN-29 
MAO-B
MAO-B-IN-15
hMAO-A, IC50: >100 μM
hMAO-B, IC50: 13.5 μM
Desoxypeganine hydrochloride
MAO-A, IC50: 2 μM
 
AChE/MAO-B-IN-4 
hMAO-B
Monoamine Oxidase B inhibitor 2
MAO-A, IC50: 1150 nM
MAO-B, IC50: 1.33 nM
(E)-CHBO4 
MAO-B, IC50: 0.023 μM
H3R antagonist 2 
MAO-B, IC50: 775 nM
AChE/BuChE/MAO-B-IN-2 
hMAO-B, IC50: 1.9 μM
MAO-B-IN-43
hMAO-A, Ki: 0.044 μM
hMAO-B, Ki: 0.004 μM
Monoamine Oxidase B inhibitor 1
MAO-A, IC50: 810 nM
MAO-B, IC50: 0.02 nM
MAO-A/SERT-IN-1
MAO-A
 
SL-25.1188 
hMAO-B, Ki: 2.9 nM
rMAO-B, Ki: 8.5 nM
Lazabemide hydrochloride 
MAO-B, IC50: 0.4 nM
AChE/MAO-IN-2
MAO-A, IC50: 0.1116 μM
MAO-B, IC50: 0.0412 μM
hAChE-IN-3 
MAO-B, IC50: 5.15 μM
MAO-B-IN-12 
MAO-B, IC50: 1.3 μM
COMT-IN-1
MAO-A, IC50: 95.58 μM
MAO-B, IC50: 58.82 μM
Methyl piperate 
MAO-B
Monoamine oxidase/Aromatase-IN-1 
MAO-B, IC50: 39 nM
Eckol
hMAO-A, IC50: 7.20 μM
hMAO-B, IC50: 83.44 μM
Dual AChE-MAO B-IN-4 
MAO-B, IC50: 15 nM
LSD1-IN-16
MAO-A, IC50: 0.024  ±   μM
MAO-B, IC50: 0.366  ±  μM
PSB-1434 
MAO-B, IC50: 1.59 nM
98.05%
BChE/MAO-B-IN-1 
MAO-B, IC50: 20 nM
AChE-IN-82
hMAO-A, IC50: 14.52 μM
hMAO-B, IC50: 0.024 μM
5-HT6R/MAO-B modulator 1 
MAO-B
MAO-B-IN-42 
MAO-B, IC50: 0.184 μM
MAO A/HSP90-IN-1
MAO-A, IC50: 1.77 μM
 
Norharmine
MAO-A
 
Fabomotizole
MAO-A
 99.96%
Tedizolid phosphate sodium
MAO-A
MAO-B
Harmane hydrochloride
hMAO-A, IC50: 0.5 μM
MAO-B, IC50: 5 μM
PSB-1410 
hMAO-B, IC50: 0.23 nM
rMAO-B, IC50: 1.01 nM
99.22%
SZV-558 
rMAO-B, IC50: 50 nM
hMAO-B, IC50: 60 nM
Brofaromine hydrochloride
MAO-A
 
2-APB hydrochloride
MAO-A
 
Acacetin 7-O-(6-O-malonylglucoside)
MAO-A, IC50: 2.34 μM
MAO-B, IC50: 1.87 μM
(-)-2-Phenylpropylamine
MAO-A, Ki: 584 μM
MAO-B, Ki: 156 μM
6,7-Dimethylisatin
MAO-A, IC50: 20.3 μM
MAO-B, IC50: 6.74 μM